Insider Buying: CorMedix (NASDAQ:CRMD) Director Purchases 25,000 Shares of Company Stock

CorMedix logo with Healthcare background
Image from MarketBeat Media, LLC.

CorMedix Inc (NASDAQ:CRMD - Get Free Report) Director Myron Kaplan acquired 25,000 shares of the firm's stock in a transaction that occurred on Monday, November 16th. The shares were purchased at an average price of $4.88 per share, with a total value of $122,000.00. Following the completion of the acquisition, the director owned 256,487 shares of the company's stock, valued at $1,251,656.56. This represents a 10.80% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

CorMedix Stock Down 3.6%

Shares of CRMD stock traded down $0.17 during trading on Wednesday, reaching $4.50. The company's stock had a trading volume of 1,600,703 shares, compared to its average volume of 1,632,172. CorMedix Inc has a one year low of $4.49 and a one year high of $13.02. The business has a fifty day moving average price of $7.04 and a 200-day moving average price of $7.54. The company has a market cap of $357.93 million, a price-to-earnings ratio of 6.52, a price-to-earnings-growth ratio of 1.11 and a beta of 1.48. The company has a quick ratio of 2.36, a current ratio of 2.43 and a debt-to-equity ratio of 0.31.

CorMedix (NASDAQ:CRMD - Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The business had revenue of $54.52 million during the quarter, compared to analyst estimates of $51.76 million. CorMedix had a net margin of 15.49% and a return on equity of 26.70%. Analysts anticipate that CorMedix Inc will post 0.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CRMD has been the subject of a number of recent analyst reports. Needham & Company LLC increased their price target on shares of CorMedix from $12.00 to $14.00 and gave the company a "buy" rating in a research note on Tuesday, November 10th. Wall Street Zen lowered shares of CorMedix from a "hold" rating to a "sell" rating in a research note on Saturday. Royal Bank Of Canada upped their target price on shares of CorMedix from $14.00 to $15.00 and gave the company an "outperform" rating in a report on Tuesday, November 10th. Weiss Ratings downgraded shares of CorMedix from a "hold (c+)" rating to a "hold (c)" rating in a research note on Tuesday, November 10th. Finally, UBS Group set a $19.00 price target on CorMedix in a report on Tuesday, November 10th. Eight analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, CorMedix currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.22.

View Our Latest Stock Analysis on CorMedix

Institutional Investors Weigh In On CorMedix

A number of institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in CorMedix in the second quarter valued at about $49,644,000. Goldman Sachs Group Inc. boosted its position in shares of CorMedix by 167.9% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,249,382 shares of the company's stock worth $9,620,000 after acquiring an additional 782,989 shares in the last quarter. Marshall Wace LLP increased its stake in CorMedix by 53.4% in the third quarter. Marshall Wace LLP now owns 1,195,422 shares of the company's stock valued at $9,205,000 after acquiring an additional 415,887 shares during the last quarter. Pacer Advisors Inc. raised its position in CorMedix by 128.7% during the first quarter. Pacer Advisors Inc. now owns 580,620 shares of the company's stock valued at $3,942,000 after purchasing an additional 326,724 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. increased its stake in shares of CorMedix by 150.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 438,629 shares of the company's stock valued at $3,443,000 after purchasing an additional 263,618 shares during the last quarter. Institutional investors own 34.18% of the company's stock.

CorMedix Company Profile

(Get Free Report)

CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CorMedix Right Now?

Before you consider CorMedix, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorMedix wasn't on the list.

While CorMedix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines